Avid Bioservices Inc (CDMO)

[biopharm]

Dmitry Gabrilovich : Peregrine Pharmaceuticals KOL :

Below is an excerpt from the annual report chronicling the role of translational medicine at The Wistar Institute and the projects of three key faculty members.

A PIONEERING PROGRAM IN TUMOR IMMUNOLOGY

June 11, 2014

In 2013, Wistar recruited internationally recognized immunologist Dmitry Gabrilovich, M.D., Ph.D., to lead a cutting-edge program of the Cancer Center in Translational Tumor Immunology.

“We have come to understand that the immune system is a critical element of tumor progression,” said Gabrilovich, who was named the Christopher M. Davis Professor at the Institute. “Our goal is to make the immune system an active focus of cancer research. We want to convert cancer into a manageable, chronic disease and give patients a better quality of life.”

Gabrilovich is developing a dual program: the first, to consider how to stimulate immune response and change the microenvironment (cells and tissues) that gives rise to tumors; the second, to combine immunotherapy with other therapies to create more effective treatment strategies.

“Immunotherapy is a complex area of biomedical research that requires a multifaceted approach to the study of science and disease,” said Gabrilovich.

“We’re building our team with accomplished scientists investigating different aspects of the regulation of the immune system,” Gabrilovich said. Over the next two years, he plans to recruit four new team members with the aim of assembling a world-class interdisciplinary team.

http://www.wistar.org/wistar-today/wistar-wire/2014-06-11/the-annual-report-translational-research